摘要
变应原特异性免疫治疗对哮喘、过敏性鼻炎有效,已广泛用于治疗Ⅰ型超敏性疾病。实验证明基于重组变应原的免疫治疗具有与天然变应原相似的效果,重组变应原被认为是免疫治疗的新型制品,有诸多的优点。基于重组变应原的免疫治疗能够改善免疫治疗临床现状,并为新的免疫治疗提供可能性。本文综述了重组尘螨变应原对哮喘和过敏性鼻炎的免疫治疗现状及进展。
Allergen-specific immunotherapy, effective for asthma and allergic rhinitis, has been widely used for the treatment of type I hypersensitivity diseases. Experiments have proved that immunotherapy based on recombinant allergens has similar effects with natural allergens. Recombinant allergens were considered as new products of immunotherapy, which have many advantages. Immunotherapy based on recombinant allergens can improve the clinical status of immunotherapy and provide the possibility of new immunotherapy. This article reviews the current status and progress of immunotherapy of recombinant dust mite allergens for asthma and allergic rhinitis.
作者
魏艳彬
于长江
岳林明
WEI Yan-bin;YU Chang-jiang;YUE Lin-ming(Digestive Diseases Hospital of Shandong First Medical University,Jining 272033,Shandong,China;Shandong First Medical University(Shandong Academy of Medical Sciences),Shandong Institute of Parasitic Disease Control)
出处
《中国病原生物学杂志》
CSCD
北大核心
2021年第7期856-858,共3页
Journal of Pathogen Biology
关键词
重组变应原
哮喘
过敏性鼻炎
免疫治疗
综述
recombinant allergens
asthma
allergic rhinitis
immunotherapy
review